Skip to main content
. 2020 Sep 24;10:559896. doi: 10.3389/fonc.2020.559896

FIGURE 2.

FIGURE 2

The prognostic value of KRAS mutational status in advanced lung adenocarcinoma. (A) Kaplan–Meier survival analysis based on KRAS mutation status. (B) KRAS-mutant patients with co-mutations have shorter overall survival than those with KRAS mutation alone. (C) Kaplan–Meier survival analysis of KRAS co-mutation subtypes. (D,E) Kaplan–Meier survival analysis of KRAS mutation subtypes G12C (D) or G > T (E) with wild-type. (F,G) Kaplan–Meier survival analysis of KRAS mutation subtypes G12C (F) or G > T (G) with concurrent STK11 mutation. MUT, mutant; WT, wild-type.